Liliana Bustamante, MD | Authors

ctDNA Assays in CRC: Interpreting Clinical Findings

October 29, 2021

Following presentation of a paper by Loupakis F, et al., Drs Liliana Bustamante and Richard Kim raise questions pertaining to the use of ctDNA as a biomarker when managing patients with metastatic colorectal cancer undergoing resection.

ctDNA as a Biomarker in CRC

October 22, 2021

An overview of what is currently understood about the use of ctDNA assays to help guide treatment decisions when managing patients with colorectal cancer undergoing resection of metastases.

Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

October 08, 2021

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” by Loupakis F, et al.